Author:
Lodi Lorenzo,Catamerò Francesco,Sarli Walter Maria,Moriondo Maria,Nieddu Francesco,Ferraro Emanuela,Citera Francesco,Astorino Valeria,Giovannini Mattia,Voarino Marta,Pelosi Caterina,Quaranta Francesca,Lippi Francesca,Canessa Clementina,Ricci Silvia,Azzari Chiara
Reference31 articles.
1. Giufr� M. ISS-Sorveglianza nazionale delle malattie batteriche invasive (MIB);C Fazio;Camilli R
2. Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use;I Yildirim;Pediatrics,2024
3. Invasive pneumococcal disease surveillance in Canada, 2021-2022;A Griffith;Canada Communicable Disease Report,2024
4. Effectiveness of 13valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study;K L Andrejko;Vaccine,2024
5. Serotype 3 Remains the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2012-2014) Despite Continued Reductions in Other 13-Valent Conjugate Vaccine Serotypes;A N Hor�cio;Front Microbiol,2016